Clinical Trial Update: Fixed Dose NESP Study in Subjects With CRI [Phase 2]

View source ↗

Summary

Amgen completed a Phase 2 fixed-dose study of NESP in subjects with chronic kidney disease not yet on dialysis (pre-dialysis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• NESP

Snippet

Sponsor: Amgen | Conditions: Pre-Dialysis | Phase 2 | Status: COMPLETED